ANVS vs. IMMX, RPHM, CELU, CALC, AEON, CKPT, ELDN, KZR, EGRX, and BLRX
Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include Immix Biopharma (IMMX), Reneo Pharmaceuticals (RPHM), Celularity (CELU), CalciMedica (CALC), AEON Biopharma (AEON), Checkpoint Therapeutics (CKPT), Eledon Pharmaceuticals (ELDN), Kezar Life Sciences (KZR), Eagle Pharmaceuticals (EGRX), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical preparations" industry.
Annovis Bio (NYSE:ANVS) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, Annovis Bio had 5 more articles in the media than Immix Biopharma. MarketBeat recorded 10 mentions for Annovis Bio and 5 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.91 beat Annovis Bio's score of -0.28 indicating that Immix Biopharma is being referred to more favorably in the news media.
Annovis Bio received 15 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 95.00% of users gave Annovis Bio an outperform vote.
Annovis Bio has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.
Immix Biopharma's return on equity of -95.00% beat Annovis Bio's return on equity.
Annovis Bio presently has a consensus target price of $23.50, suggesting a potential upside of 243.07%. Immix Biopharma has a consensus target price of $14.00, suggesting a potential upside of 548.15%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Annovis Bio.
Immix Biopharma is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.
15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 38.3% of Annovis Bio shares are owned by company insiders. Comparatively, 55.9% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Immix Biopharma beats Annovis Bio on 9 of the 15 factors compared between the two stocks.
Get Annovis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Annovis Bio Competitors List
Related Companies and Tools
